Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company's mission is to enhance patient outcomes through improved decision-making and personalized cancer care. Allarity Therapeutics is headquartered in Boston, MA, with an R&D facility in Hoersholm, Denmark.

The company leverages its proprietary Drug Response Predictor (DRP®) technology, a diagnostic platform that analyzes transcriptional changes in tumor cells to predict drug response. This technology aims to refine patient selection and improve clinical outcomes by matching patients to the right drug. Allarity's primary focus is the clinical development of stenoparib, a dual PARP1/2 and tankyrase 1/2 inhibitor, for the treatment of advanced, recurrent ovarian cancer. The DRP® platform is co-developed with stenoparib as a companion diagnostic.

In 2024, Allarity Therapeutics strategically refocused its efforts exclusively on stenoparib, discontinuing other clinical programs. The company received FDA Fast Track designation for stenoparib in advanced ovarian cancer in August 2025. Recent leadership appointments include Jeremy R. Graff as President and Chief Development Officer in October 2024, and Jeff Ervin as Chief Financial Officer in July 2025. Thomas H. Jensen serves as the Chief Executive Officer since December 2023. In March 2026, Allarity closed a $20 million non-convertible debt financing to accelerate stenoparib's development and extend its cash runway into mid-2028. The company also announced in February 2026 that a VA-funded Phase 2 trial combining stenoparib with temozolomide in relapsed small cell lung cancer is open for enrollment.